Benjamin Carr, Ph.D. 👨🏻‍💻🧬<p><a href="https://hachyderm.io/tags/China" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>China</span></a> has a big <a href="https://hachyderm.io/tags/STD" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>STD</span></a> problem with <a href="https://hachyderm.io/tags/supergonorrhea" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>supergonorrhea</span></a>, study finds<br><a href="https://hachyderm.io/tags/DrugResistant" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>DrugResistant</span></a> <a href="https://hachyderm.io/tags/gonorrhea" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>gonorrhea</span></a> is a growing problem—one that doesn't heed borders<br>Study surveyed gonorrhea—Neisseria gonorrhoeae—from around China and found prevalence of <a href="https://hachyderm.io/tags/ceftriaxone" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>ceftriaxone</span></a>-resistant isolates nearly tripled between 2017 and 2021. Ceftriaxone-resistant strains made up roughly 8% of the nearly 3,000 bacterial isolates collected from gonorrhea infections in 2022. That's up from just under 3% in 2017. <br> <a href="https://arstechnica.com/science/2024/03/super-gonorrhea-rate-quickly-triples-in-china-now-40x-higher-than-us/" rel="nofollow noopener" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">arstechnica.com/science/2024/0</span><span class="invisible">3/super-gonorrhea-rate-quickly-triples-in-china-now-40x-higher-than-us/</span></a></p>